A fraught Senate Finance Committee hearing, where HHS Secretary Robert F. Kennedy Jr. clashed with Republicans and Democrats alike, has led to some fallout.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
